Evidence map›Paper›PMID 30032312›Full record

ArticlePediatric cardiology2018

Hepatic Changes in the Fontan Circulation: Identification of Liver Dysfunction and an Attempt to Streamline Follow-up Screening.

T Ackerman, A Geerts, H Van Vlierberghe, J De Backer, K François

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Pediatric cardiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 19 citations in OpenAlex.

  1. Fontan-Associated Liver Disease.Seminars in liver disease · 2025
    Review
  2. Observational
  3. Article
  4. Review
  5. Clinical complications of liver disease in adults after the Fontan operation.International journal of cardiology. Congenital heart disease · 2022
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

T AckermanDepartment of Cardiac Surgery, University Hospital Ghent, De Pintelaan 185, 9000, Ghent, Belgium. thomas.ackerman@ugent.be.ORCID http://orcid.org/0000-0003-2575-627X
A GeertsDepartment of Hepatology, University Hospital Ghent, Ghent, Belgium.
H Van VlierbergheDepartment of Hepatology, University Hospital Ghent, Ghent, Belgium.
J De BackerDepartment of Cardiology, University Hospital Ghent, Ghent, Belgium.
K FrançoisDepartment of Cardiac Surgery, University Hospital Ghent, De Pintelaan 185, 9000, Ghent, Belgium.
Ghent University Hospital · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We tried to identify structural and functional liver aberrances in a palliated Fontan population and sought to determine useful screening modalities, in order to propose a screening protocol to detect patients at risk. Twenty nine patients, median age 23.7 years (interquartile range (IQR) 20.5-27.2) and median Fontan interval 19.7 years (IQR 4.5-21.4), were prospectively studied with echocardiography, blood analysis (including serum fibrosis scores Forns, APRI and FIB4), liver imaging (ultrasound (US), Doppler), and shear wave elastography to determine liver stiffness (LS). Laboratory tests predominantly showed abnormal values for gamma-glutamyltransferase. Forns index indicated moderate fibrosis in 29% of patients and correlated with Fontan interval (p = 0.034). US liver morphology was deviant in 46% of patients, with surface nodularity in 21% and nodular hyperplasia in 29%. Doppler assessment of flow velocities was within normal ranges for most patients. LS (mean 10.4 ± 3.7 kPa) was elevated in 96% of our population and higher LS values were significantly related to longer Fontan interval (p = 0.018). Adolescent and adult Fontan patients show moderate signs of liver dysfunction. Usefulness of serum parameters and fibrosis scores in post-Fontan screening remains ambiguous. The high percentage of morphologic liver changes in palliated patients supports the use of US in periodic follow-up. LS likely overestimates fibrosis due to liver congestion, arguing for the need of validation through sequential measurements. Screening should minimally encompass US assessment in combination with selective liver fibrosis scores. The role of LS measurement in Fontan follow-up and liver screening needs to be further elucidated.

Indexed as

AdultEchocardiographyElasticity Imaging TechniquesFemaleFollow-Up StudiesFontan ProcedureHumansLiver DiseasesMaleProspective StudiesUltrasonography, DopplerYoung AdultCardiac hepatopathyElastographyFontan circulationScreeningSerum markersUniventricular heart

Identifiers

PMID30032312
OpenAlexW2884553545

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.